Biobanks of human & population samples

01Overview and value chain

Markers: [EC: GDPR + EU In Vitro Diagnostic Regulation (biospecimen handling) | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

Biobanks of human and population samples are the physical infrastructure — consent, collection, cryopreservation, cataloguing, storage and distribution — that turns blood, tissue and DNA specimens from hundreds of thousands of participants into a usable research and clinical resource, distinct from the genomic data repositories and databases built on top of that biospecimen collection. UK Biobank has recruited and follows roughly 500,000 UK participants, and its linked biospecimens and health data underpin a continuous stream of published genomic and epidemiological research. BioLife Solutions supplies the biopreservation media and cold-chain technology (CryoStor, BloodStor, CellSeal CryoCase) that biobanks and cell/gene-therapy manufacturers depend on to keep specimens viable through freeze, storage and thaw. Discovery Life Sciences procures and processes human biospecimens — including legacy specimen collections it calls the “Vintage Collection” — as a service for pharma and biotech genomic-biomarker and companion-diagnostic programs. The China National GeneBank (CNGB), operated in Shenzhen, is one of the world’s largest biological-resource repositories. In India, the government inaugurated the Phenome-India National Biobank at CSIR-IGIB in 2025, launching the country’s own longitudinal population-scale biospecimen and phenotype data study.

The key directions of biobanks of human and population samples are:

1. Population biobanking (Population Biobanking): large-scale, consented biospecimen and health-data cohorts recruited for long-term research use — UK Biobank, Phenome-India National Biobank.
2. Biopreservation technology (Biopreservation Media): cryopreservation media, cold-chain packaging and freeze/thaw protocols keeping specimens and cell/gene-therapy products viable — BioLife Solutions.
3. Biospecimen procurement services (Biospecimen Procurement): contract collection, processing and supply of human biospecimens for pharma/biotech research programs — Discovery Life Sciences.
4. National biobank infrastructure (National Biobank Infrastructure): government- or state-affiliated large-scale repositories serving as a country’s standing biological-resource base — China National GeneBank.

Sectoral value chain

[consent & sample collection] ──> [processing & cryopreservation] ──> [cataloguing & data linkage]
                                                    │
                                       (cold-chain storage maintenance)
                                                    │
                                                    ▼
[longitudinal data linkage & re-consent] <─── [distribution to researchers/pharma] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Population cohort biobanking (Population Biobanking): large, consented cohorts (UK Biobank’s roughly 500,000 participants) linked to health records provide the statistical power for genome-wide association and epidemiological studies.
• Biopreservation media (Biopreservation Media): validated cryoprotectant formulations (BioLife Solutions’ CryoStor/BloodStor) control ice-crystal formation and osmotic stress during freeze/thaw to keep cells and tissue viable.
• Biospecimen procurement networks (Biospecimen Procurement): contract specimen-sourcing networks (Discovery Life Sciences) supply pharma biomarker-discovery and companion-diagnostic development programs with consented, annotated human tissue.

02US

The US hosts the commercial biopreservation-technology and biospecimen-procurement service layer that biobanks worldwide depend on, rather than a single dominant population biobank of UK Biobank’s scale.

BioLife Solutions, Discovery Life Sciences, FDA

• BioLife Solutions: supplies CryoStor and BloodStor biopreservation media and CellSeal CryoCase cold-chain packaging, the cryopreservation technology layer used across biobanking and cell/gene-therapy manufacturing.
• Discovery Life Sciences: procures and processes human biospecimens, including its “Vintage Collection” of legacy specimens, as a contract service for pharma and biotech genomic-biomarker and companion-diagnostic (CDx) programs.
• FDA framework: biospecimen handling and biopreservation products used in FDA-regulated diagnostic or cell/gene-therapy manufacturing chains fall under the relevant device/biologics quality requirements, while biobank data use for research is separately governed by human-subjects and privacy rules.

03CN

China operates one of the world’s largest biological-resource repositories through the China National GeneBank in Shenzhen.

China National GeneBank, NMPA

• China National GeneBank (CNGB): operated in Shenzhen, CNGB is among the world’s largest biological-resource repositories, storing biospecimens and genomic resources as part of China’s national biotechnology infrastructure.
• NMPA framework: biospecimen collection, storage and cross-border transfer in China operate under national human genetic resource regulations alongside NMPA’s broader biotechnology and diagnostics oversight.

04EU

The UK anchors Europe’s population-biobanking capacity through UK Biobank, one of the world’s most heavily used research biobanks.

UK Biobank, GDPR

• UK Biobank: has recruited and follows roughly 500,000 UK participants, with its linked biospecimens and health data underpinning a continuous stream of published genomic and epidemiological research across cardiovascular, oncology and neurological disease.
• GDPR/IVDR framework: UK and EU biobanks handle participant biospecimens and linked health data under GDPR data-protection requirements, with any paired in-vitro diagnostic use of biobank specimens additionally subject to IVDR 2017/746.

05Leading companies and research institutes

06Tech stack and innovations

The stack pairs population-scale cohort recruitment and consent infrastructure with validated cryopreservation chemistry and cold-chain logistics to keep specimens usable for research decades after collection.

1. Population cohort recruitment and linkage (Population Biobanking):
   • UK Biobank and the newly launched Phenome-India National Biobank recruit large, consented participant cohorts and link their biospecimens to longitudinal health and phenotype records, the statistical foundation for genome-wide association studies.
2. Cryopreservation chemistry (Biopreservation Media):
   • BioLife Solutions’ CryoStor and BloodStor media control ice-crystal formation and osmotic stress during freezing, and CellSeal CryoCase packaging maintains cold-chain integrity during transport.
3. Contract biospecimen procurement (Biospecimen Procurement):
   • Discovery Life Sciences sources, processes and annotates human biospecimens (including legacy “Vintage Collection” material) to supply pharma genomic-biomarker discovery and companion-diagnostic development pipelines.
4. National biobank infrastructure (National Biobank Infrastructure):
   • The China National GeneBank and India’s Phenome-India National Biobank represent government-backed, large-scale repository infrastructure intended as a standing national biological-resource base rather than a single research project.

07Value chains and production pipelines

Industrial pipeline of a population biobank (GDPR / EU IVDR biospecimen handling)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Consent & sample       │ ───> │ 2. Processing &           │
│    collection              │      │    cryopreservation         │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Cold-chain storage     │ <─── │ 3. Cataloguing & data     │
│                            │      │    linkage                  │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Distribution to        │ ───> │ 6. Longitudinal linkage & │
│    researchers/pharma      │      │    re-consent                │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Consent and sample collection

Participants are recruited under an informed-consent protocol, and blood, tissue or saliva specimens are collected at clinical or field sites, whether for a national population cohort (UK Biobank, Phenome-India) or a contract biospecimen program (Discovery Life Sciences).

Stage 2: Processing and cryopreservation

The raw specimen is processed and frozen using validated biopreservation media (BioLife Solutions’ CryoStor/BloodStor) formulated to control ice-crystal formation and osmotic stress during freeze and thaw.

Stage 3: Cataloguing and data linkage

Each specimen is catalogued in a laboratory information management system (LIMS) and linked to the participant’s consented health and phenotype data, creating the searchable biobank record researchers query against.

Stage 4: Cold-chain storage

Specimens are held in temperature-controlled storage (typically -80°C or liquid nitrogen) for years to decades, with cold-chain packaging (CellSeal CryoCase) maintaining viability during any transport between sites.

Stage 5: Distribution to researchers and pharma

Approved research or pharma-industry access requests are fulfilled with specimens and/or linked data, supporting genome-wide association studies, biomarker discovery and companion-diagnostic development.

Stage 6: Longitudinal linkage and re-consent

Large population biobanks continue linking participant health records over years, periodically re-consenting cohorts for new data types or research uses as the biobank’s scientific value compounds over time.